Infliximab optimisation in ulcerative colitis: Intensificated and deintensificated patients clinical outcome

被引：0
|
作者：
Fernandez-Salazar, L. [1 ]
Barrio, J. [2 ]
Legido, J. [3 ]
Munoz, C. [4 ]
Gonzalez, G. [1 ]
S-Ocana, R. [2 ]
Santos, F. [2 ]
Velayos, B. [1 ]
Gonzalez, J. M. [1 ]
机构：
[1] Hosp Clin Univ, Gastroenterol, Valladolid Acad, Spain
[2] Hosp Univ Rio Hortega, Gastroenterol, Valladolid, Spain
[3] Complejo Asistencial Segovia, Gastroenterol, Segovia Acad, Spain
[4] Hosp Virgen Salud, Gastroenterol, Toledo Acad, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷
关键词：
D O I：
10.1016/S1873-9946(14)60584-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P464
引用
收藏
页码：S260 / S260
页数：1
相关论文
共 50 条
  • [1] Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis
    Reinisch, Walter
    Feagan, Brian G.
    Rutgeerts, Paul J.
    Adedokun, Omoniyi J.
    Cornillie, Freddy J.
    Diamond, Robert
    Marano, Colleen W.
    Sandborn, William J.
    GASTROENTEROLOGY, 2012, 142 (05) : S114 - S114
  • [2] Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission
    Munoz Villafranca, Carmen
    Bravo Rodriguez, Maria Teresa
    Ortiz de Zarate, Jone
    Arreba Gonzalez, Paz
    Garcia Kamiruaga, Inigo
    Heras Martin, Juan Ignacio
    Cabezudo Gil, Pilar
    Orive Cura, Victor
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2016, 39 (07): : 442 - 448
  • [3] Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus
    Nakase, H.
    Yamamoto, S.
    Matsuura, M.
    Honzawa, Y.
    Chiba, T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (03) : 510 - 511
  • [4] Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
    Seow, C. H.
    Newman, A.
    Irwin, S. P.
    Steinhart, A. H.
    Silverberg, M. S.
    Greenberg, G. R.
    GUT, 2010, 59 (01) : 49 - 54
  • [5] The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab
    Dumitrescu, G.
    Amiot, A.
    Seksik, P.
    Baudry, C.
    Stefanescu, C.
    Gagniere, C.
    Allez, M.
    Cosnes, J.
    Bouhnik, Y.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (10) : 1192 - 1199
  • [6] Infliximab for patients with refractory ulcerative colitis
    Chey, WY
    INFLAMMATORY BOWEL DISEASES, 2001, 7 : S30 - S33
  • [7] Trough serum infliximab predicts outcome for ulcerative colitis treatment with infliximab
    Seow, Cynthia H.
    Silverberg, Mark S.
    Newman, Alvin
    Steinhart, A. Hillary
    Greenberg, Gordon R.
    GASTROENTEROLOGY, 2008, 134 (04) : A659 - A659
  • [8] Association of Serum Infliximab and Antibodies to Infliximab to Long-Term Clinical Outcome in Acute Ulcerative Colitis
    Murthy, Sanjay
    Kevans, David
    Seow, Cynthia H.
    Newman, Alvin
    Steinhart, A. Hillary
    Silverberg, Mark S.
    Greenberg, Gordon R.
    GASTROENTEROLOGY, 2012, 142 (05) : S388 - S388
  • [9] Outcome Following Infliximab Therapy in Children With Ulcerative Colitis
    Hyams, Jeffrey S.
    Lerer, Trudy
    Griffiths, Anne
    Pfefferkorn, Marian
    Stephens, Michael
    Evans, Jonathan
    Otley, Anthony
    Carvalho, Ryan
    Mack, David
    Bousvaros, Athos
    Rosh, Joel
    Grossman, Andrew
    Tomer, Gitit
    Kay, Marsha
    Crandall, Wallace
    Oliva-Hemker, Maria
    Keljo, David
    LeLeiko, Neal
    Markowitz, James
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (06): : 1430 - 1436
  • [10] Infliximab outcome in children and adults with ulcerative colitis.
    Kugathasan, S
    Prajapati, DN
    Kim, JP
    Saeian, K
    Emmons, J
    Knox, J
    Rivera-Bennett, T
    Werlin, SL
    Binion, DG
    GASTROENTEROLOGY, 2002, 122 (04) : A615 - A615
12345